{"id":121959,"date":"2021-04-20T13:04:44","date_gmt":"2021-04-20T13:04:44","guid":{"rendered":"https:\/\/precoinnews.com\/?p=121959"},"modified":"2021-04-20T13:04:44","modified_gmt":"2021-04-20T13:04:44","slug":"johnson-johnson-coronavirus-vaccine-delivers-100m-in-sales","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/markets\/johnson-johnson-coronavirus-vaccine-delivers-100m-in-sales\/","title":{"rendered":"Johnson & Johnson coronavirus vaccine delivers $100M in sales"},"content":{"rendered":"
Dr. Devi Nampiaparampil provides insight into the Johnson & Johnson vaccine and long-term effects of coronavirus.<\/p>\n
Johnson & Johnson raked in $100 million in first-quarter sales from its single-shot COVID-19 vaccine that was put on hold last week by the U.S. Food and Drug Administration. <\/p>\n
The New Brunswick, New Jersey-based drugmaker did not provide an update on the state of the vaccine alongside its quarterly results, but is expected to do so later this week. <\/p>\n
Ticker<\/th>\n | Security<\/th>\n | Last<\/th>\n | Change<\/th>\n | Change %<\/th>\n<\/tr>\n<\/thead>\n |
---|---|---|---|---|
JNJ<\/td>\n | JOHNSON & JOHNSON<\/td>\n | 162.64<\/td>\n | +0.30<\/td>\n | +0.18%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n "Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices," CEO Alex Gorsky said in a statement. <\/p>\n Net earnings in the three months through March rose 6.9% year over year to $6.2 billion, or an adjusted $2.59 per diluted share. Revenue was $22.32 billion.<\/p>\n Wall Street analysts surveyed by Refinitiv were expecting adjusted earnings of $2.34 per share on revenue of $21.98 billion.<\/p>\n Pharmaceutical sales, which made up 55% of all revenue, increased 9.6% from a year ago to $12.2 billion. Stelara, a treatment for Crohn's disease and plaque psoriasis, saw sales climbed 18% to $2.15 billion. Sales of Cancer drug Darzalex jumped 46% to $1.37 billion.<\/p>\n Elsewhere, medical device sales rose 11% to $6.6 bullion while consumer health revenue fell 2.3% to $3.5 billion.<\/p>\n The strong results compelled the company's board of directors to raise the divided by 5 cents to $1.06 per share. <\/p>\n CLICK HERE TO READ MORE ON FOX BUSINESS<\/u><\/strong><\/p>\n Looking ahead, Johnson & Johnson tweaked its full-year adjusted profit forecast to between $9.42 and $9.57 per share versus its prior forecast of $9.40 to $9.60 per share. <\/p>\n Johnson & Johnson shares were up 3.37% this year through Monday compared with the S&P 500's 11% gain. <\/p>\n |